Dogwood Therapeutics (NASDAQ:DWTX) Trading 5.4% Higher – Here’s What Happened

Dogwood Therapeutics, Inc (NASDAQ:DWTX) traded up 5.4% on Thursday . The company traded as high as $1.6050 and last traded at $1.57. 266,441 shares traded hands during mid-day trading, an increase of 432% from the average session volume of 50,078 shares. The stock had previously closed at $1.49.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Weiss Ratings downgraded shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Dogwood Therapeutics in a report on Tuesday, May 19th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Trading Up 5.4%

The company has a fifty day simple moving average of $1.70 and a 200-day simple moving average of $3.06. The stock has a market cap of $52.80 million, a price-to-earnings ratio of -0.15 and a beta of 1.70.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. As a group, analysts anticipate that Dogwood Therapeutics, Inc will post -0.55 earnings per share for the current year.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.